CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
For research use only. We do not sell to patients.
Name | CMP3a |
---|---|
Iupac Chemical Name | (R)-5-{7-[1-(2-Dimethylamino-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}-3-[1-(2-trifluoromethyl-phenyl)-ethoxy]-thiophene-2-carboxamide |
Synonyms | CMP3a; CMP-3a; CMP 3a. |
Molecular Formula | C28H27F3N6O2S |
Molecular Weight | 568.61 |
Smile | O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(C3=CN=C4C=C(C5=CN(CCN(C)C)N=C5)C=CN43)S1)N |
InChiKey | BQODGOMHYSMCGK-QGZVFWFLSA-N |
InChi | InChI=1S/C28H27F3N6O2S/c1-17(20-6-4-5-7-21(20)28(29,30)31)39-23-13-24(40-26(23)27(32)38)22-15-33-25-12-18(8-9-37(22)25)19-14-34-36(16-19)11-10-35(2)3/h4-9,12-17H,10-11H2,1-3H3,(H2,32,38)/t17-/m1/s1 |
CAS Number | 647834-15-9 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A,
Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum
HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and
radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest.
2017 Aug 1;127(8):3075-3089. doi: 10.1172/JCI89092. Epub 2017 Jul 24. PubMed
PMID: 28737508; PubMed Central PMCID: PMC5531394.